Sarah Sammons, Md

This study tests whether combining two drugs—elacestrant and trastuzumab deruxtecan—can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2-low) that no longer responds to standard hormone therapy or CDK4/6 inhibitors. About 65 participants will recei…